| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | DPR2; DAPPER2; C6orf116; bA503C24.7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human DACT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DACT2抗体的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**: "DACT2 Suppresses Hepatocellular Carcinoma Progression by Modulating Wnt/β-Catenin Signaling"
**作者**: Li X, Zhang Y, et al.
**摘要**: 本研究通过免疫组化(使用兔源DACT2多克隆抗体)和Western blot分析，发现DACT2在肝癌组织中表达显著下调。功能实验表明，DACT2通过抑制Wnt/β-catenin信号通路抑制肿瘤侵袭，提示其作为肝癌预后标志物的潜力。
2. **文献名称**: "Epigenetic Silencing of DACT2 Promotes Colorectal Cancer Metastasis"
**作者**: Wang H, Chen J, et al.
**摘要**: 文章利用抗DACT2单克隆抗体(克隆号AB-3C7)检测结直肠癌组织中DACT2蛋白表达，发现其启动子高甲基化导致表达缺失，并通过调控TGF-β信号促进肿瘤转移，为靶向表观遗传治疗提供依据。
3. **文献名称**: "Development and Validation of a High-Specificity DACT2 Antibody for Immunofluorescence Applications"
**作者**: Kumar R, Lee S, et al.
**摘要**: 本研究报道了一种新型小鼠抗DACT2单克隆抗体的开发，经ELISA、免疫沉淀和免疫荧光验证显示高特异性。该抗体成功应用于胚胎发育研究中DACT2的亚细胞定位分析。
4. **文献名称**: "DACT2 as a Tumor Suppressor in Gastric Cancer: Correlation with Clinicopathological Features"
**作者**: Tanaka M, Suzuki K, et al.
**摘要**: 通过DACT2抗体(购自Abcam, ab12345)进行组织芯片分析，发现DACT2低表达与胃癌患者生存率降低相关，其缺失通过激活Wnt信号促进肿瘤增殖，提示其临床预后价值。
(注：以上文献名为虚构，如需真实文献建议通过PubMed/Google Scholar以“DACT2 antibody”或“DACT2 + [疾病/通路]”为关键词检索。)
DACT2 (Dapper Homolog 2), a member of the Dapper (DACT) gene family, is a cytoplasmic protein involved in regulating Wnt signaling pathways, particularly by modulating β-catenin-dependent and -independent pathways. It acts as a scaffold protein, interacting with key components like Dishevelled (Dvl) to inhibit or enhance Wnt signaling, depending on cellular context. DACT2 is implicated in embryonic development, tissue homeostasis, and cancer progression. Research highlights its tumor-suppressive role in multiple cancers, including colorectal, gastric, and hepatocellular carcinomas, where its expression is frequently downregulated due to promoter hypermethylation. This epigenetic silencing correlates with advanced tumor stages, metastasis, and poor prognosis.
DACT2 antibodies are critical tools for investigating its expression patterns, functional mechanisms, and clinical relevance. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence to detect protein levels in tissues or cell lines. Commercially available polyclonal or monoclonal antibodies target specific epitopes, aiding in studies exploring DACT2’s interaction networks and post-translational modifications. Recent studies also utilize these antibodies to validate DACT2’s role in suppressing epithelial-mesenchymal transition (EMT) and metastasis via Wnt/β-catenin pathway inhibition. As DACT2 gains attention as a potential biomarker or therapeutic target, its antibodies remain essential for both basic research and translational applications in oncology.
×
